Loading
institutionsInstitution
City of Hope
Los Angeles cancer centre where synthetic insulin and humanised antibodies were developed; a CAR-T manufacturing leader.
Overview
City of Hope in Duarte, near Los Angeles, is an NCI comprehensive cancer centre where synthetic insulin and humanised antibodies were developed, and it is now a leader in CAR-T manufacturing and in CAR-T for brain tumours. Christine E. Brown and Behnam Badie developed IL13Rα2 CAR-T for glioblastoma, the centre runs in-house cell manufacturing and a large transplant programme, and it acquired Cancer Treatment Centers of America, with Robert W. Stone, Steven T. Rosen, Stephen J. Forman, Michael A. Caligiuri, Hope S. Rugo and Alex F. Herrera among the people OnCo lists. OnCo links it to glioma and paediatric neuroblastoma, to the idea of delivering CAR-T straight into the cerebrospinal fluid, and to City of Hope Orange County. The brain as a barrier and sanctuary is the bottleneck its flagship programme confronts. Its CAR-T for glioma and transplant programmes are the ones to read.
Location
Duarte, CA, US
Type
cancer center
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#128 · 35 points (0 Newsweek + 15 NCI + 20 from 10 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to City of Hope, including child institutions. 1,539 works · 19,555 citations · 64% open access · 18% clinical trials · 1% reviews.
Oncology works per year
2552022
3352023
3452024
3632025
2412026
Most works
- Marwan Fakih118 works
- Stephen J. Forman99 works
- Christine E. Brown52 works
- Ibrahim Taha Aldoss48 works
- Saul J. Priceman47 works
- Sumanta K. Pal47 works
- Alex F. Herrera43 works
- Xiuli Wang40 works
- Lihua Elizabeth Budde38 works
- Joanne E. Mortimer36 works
Most cited
- CAR-T for glioma
- Transplant
Alex F. Herrera
Chief, Division of Lymphoma, City of Hope; SWOG Executive Officer, Leukemia/Lymphoma/Myeloma
Hodgkin lymphomaImmunotherapyCooperative group trials
Led the SWOG S1826 trial that made nivolumab part of first-line Hodgkin lymphoma treatment.
Annette Walker
President of City of Hope Orange County
Health system leadershipCancer campus developmentHealthcare strategy
Health system executive who leads City of Hope Orange County and oversaw the opening of Orange County's first cancer specialty hospital in Irvine.
Behnam Badie
Chief, Division of Neurosurgery, City of Hope
Neurosurgical oncologyGliomaCAR-T delivery
Neurosurgeon who delivers CAR-T cells directly into the brain in City of Hope's glioma trials.
Christine E. Brown
Deputy Director, T Cell Therapeutics Research Laboratories, City of Hope
CAR-T cell therapyGlioblastomaRegional delivery
Engineered the IL13Rα2 CAR-T cells that produced a complete response in glioblastoma when infused into the brain.
Hope S. Rugo
Division Chief, Breast Medical Oncology; Director, Women's Cancers Program, City of Hope
Breast cancerADCsSupportive care
Breast oncologist who led key ADC and CDK4/6 trials and moved from UCSF to City of Hope in 2024.
Michael A. Caligiuri
President, City of Hope National Medical Center; Deana and Steve Campbell Physician-in-Chief; AACR Treasurer
Natural killer cellsLeukaemiaImmunotherapy
Michael Caligiuri is an NK cell immunologist and past AACR president who leads City of Hope's hospital.
Robert W. Stone
President and Chief Executive Officer, City of Hope
Health system leadership
Leads City of Hope, which expanded into a national cancer system with the acquisition of Cancer Treatment Centers of America.
Stephen J. Forman
Director, Hematologic Malignancies Research Institute; Francis and Kathleen McNamara Distinguished Chair, City of Hope
Hematopoietic cell transplantationCAR-TLymphoma
Transplant pioneer who built City of Hope's cell therapy programme, one of the largest in the country.
Steven T. Rosen
Provost and Chief Scientific Officer; Director, Beckman Research Institute, City of Hope
LymphomaCancer research leadershipTranslational science
Steven Rosen is a lymphoma specialist who directs City of Hope's research enterprise.
Sumanta K. Pal
Professor and Co-Director, Kidney Cancer Program, City of Hope
Renal cell carcinomaNon-clear-cell histologiesMicrobiome and immunotherapy
Led SWOG 1500, the first randomised trial to set a standard for papillary kidney cancer, and studies of the microbiome in RCC immunotherapy.
Virginia Sun
Professor, Population Sciences and Surgery, City of Hope; SWOG Executive Officer, Palliative Care and Survivorship
SurvivorshipPalliative careSymptom science
Virginia Sun is a nurse scientist who leads SWOG's supportive care and survivorship research.
Yuman Fong
Chair, Department of Surgery, City of Hope
Hepatobiliary surgeryLiver metastasesOncolytic viruses
Liver surgeon who defined who benefits from resecting colorectal liver metastases and pioneered oncolytic virus therapy.
Similar pages
- TechnologyArmoured, logic-gated & next-gen CARs
Shares Christine E. Brown, CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), Neuroblastoma (paediatric), CAR-T cell therapy.
- IdeaOpen the barrier so engineered immune cells can enter the brain
Shares CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), The brain: barrier and sanctuary, CAR-T cell therapy, Glioma & glioblastoma.
- InstitutionStanford Health Care / Stanford Cancer Institute
Shares Biology-guided radiotherapy (RefleXion X1, SCINTIX), CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), Parker Institute for Cancer Immunotherapy, The brain: barrier and sanctuary.
- TermEGFRvIII
Shares CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), The brain: barrier and sanctuary, Glioma & glioblastoma.
- InstitutionChao Family Comprehensive Cancer Center, UC Irvine
Shares City of Hope Orange County, National Cancer Institute (NIH).
- IdeaNeoadjuvant immunotherapy with surgical window for glioblastoma
Shares CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), The brain: barrier and sanctuary, Glioma & glioblastoma.
- InstitutionThe Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute
Shares Michael A. Caligiuri, National Cancer Institute (NIH).
- TermH3 K27M (diffuse midline glioma)
Shares CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), The brain: barrier and sanctuary, Glioma & glioblastoma.